Hermetica Superfood Encyclopedia
Banisteriopsis caapi is a South American vine containing harmala alkaloids like harmine and harmaline. These compounds primarily act as reversible monoamine oxidase-A (MAO-A) inhibitors, modulating neurotransmitter levels.
Origin & History
Banisteriopsis caapi is a woody vine native to the Amazon rainforest in South America, belonging to the Malpighiaceae family, primarily used in traditional preparations like ayahuasca. The source organism is the stem bark of the plant, with extracts typically prepared by decoction (boiling) in water, yielding a crude extract containing beta-carboline alkaloids including harmine, harmaline, and tetrahydroharmine.
Scientific Research
Clinical evidence is extremely limited, consisting only of historical case series from the 1920s at Neukoelln Hospital using subcutaneous banisterine (25-70mg) for postencephalitic parkinsonism, and one referenced trial with 30 de novo Parkinson's patients (15 receiving 200mL oral extract), though no PMIDs or controlled study designs are available. Modern research is restricted to in vitro studies using SH-SY5Y neuroblastoma and BV-2 microglial cell lines.
Preparation & Dosage
Historical clinical use: 25-70mg banisterine (harmine) subcutaneously for neurological conditions; 200mL oral B. caapi extract for Parkinson's patients (non-standardized). In vitro studies used 0.1% extract concentration or harmine at 3-30μM. No standardized dosages or modern clinical recommendations exist. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
Banisteriopsis caapi vine bark and stems contain negligible macronutrient value as a dietary source; it is consumed primarily as a medicinal/ceremonial preparation rather than a food. Bioactive alkaloid content is the primary area of characterization: beta-carboline alkaloids dominate the profile, with harmine typically present at 0.2–4.0% dry weight (most concentrated compound), harmaline at 0.03–0.5% dry weight, and tetrahydroharmine (THH) at 0.05–0.4% dry weight; concentrations vary significantly by plant age, geographic origin, and preparation method. Trace alkaloids including harmol, harmalol, and norharmine are detected in smaller quantities (<0.05% dry weight). Tannins and procyanidins are present in the bark at moderate concentrations (estimated 2–8% dry weight), contributing astringency. Phenolic acids including caffeic acid and ferulic acid derivatives have been identified via HPLC analysis in aqueous extracts. Saponins are present at low levels. Conventional micronutrients (vitamins B, C, E; minerals such as magnesium, potassium, calcium) are present only in trace amounts typical of woody plant material and contribute no meaningful nutritional value at ceremonial doses (typically 50–150g fresh vine per preparation). Bioavailability note: harmine and harmaline are orally bioavailable; harmaline is rapidly reduced to THH in vivo; beta-carbolines act as reversible MAO-A inhibitors, which directly affects bioavailability of co-administered tryptamines in ayahuasca preparations. Fiber content exists as structural lignocellulosic material but is not nutritionally relevant in decoction-based preparations.
How It Works
Banisteriopsis caapi's primary active compounds, harmine and harmaline, reversibly inhibit monoamine oxidase-A (MAO-A). This enzymatic inhibition prevents the breakdown of monoamine neurotransmitters such as serotonin, dopamine, and norepinephrine, increasing their synaptic availability. Additionally, tetrahydroharmine acts as a weak selective serotonin reuptake inhibitor (SSRI), further influencing serotonin signaling.
Clinical Evidence
Historical case series from the 1920s suggested Banisteriopsis caapi's potential for neurological support, though these lacked modern controlled trial rigor or quantitative outcomes. Current human evidence for its benefits is extremely limited, with no large-scale clinical studies confirming its traditional uses. In vitro cell studies demonstrate anti-inflammatory effects by reducing pro-inflammatory cytokines like IL-6, but these findings have not been replicated in living organisms or human trials.
Safety & Interactions
Due to its MAO-inhibiting properties, Banisteriopsis caapi poses significant risks for interactions. It should not be combined with SSRIs, SNRIs, tricyclic antidepressants, or other MAOIs, as this can lead to serotonin syndrome. Interactions with tyramine-rich foods (aged cheeses, cured meats) can cause hypertensive crisis. Common side effects include nausea, vomiting, and diarrhea. It is contraindicated in individuals with cardiovascular conditions, liver disease, or certain mental health disorders, and its use is strongly discouraged during pregnancy and breastfeeding.
Also Known As
Frequently Asked Questions
What is Banisteriopsis caapi?
What are the primary active compounds in Banisteriopsis caapi?
How does Banisteriopsis caapi influence brain function?
What are the potential side effects associated with Banisteriopsis caapi?
Can Banisteriopsis caapi be safely combined with other medications or supplements?
What does the research evidence show about Banisteriopsis caapi's effectiveness?
Who should avoid Banisteriopsis caapi due to safety concerns?
How is Banisteriopsis caapi typically prepared and does preparation method affect its activity?
Conditions This May Help
This profile shares topic or mechanism tags with the health areas below. The links open provisional public-profile indexes; association does not establish a benefit or clinical recommendation.
Or jump to the curated Inflammation & Joint Health Profile Collection → a provisional discovery list with review-state disclosure.
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.